Lenacapavir shows 96% HIV prevention success

A six-monthly HIV prevention injection containing lenacapavir has been confirmed effective in two pivotal studies. The first study, PURPOSE 1, showed no HIV infections among two-thousand-134 participants, while the second, PURPOSE 2, reported two infections among two-thousand-179 participants. This translates to a 96-percent reduction in HIV infections compared to background incidence. Gilead Sciences plans to file for regulatory approval to market lenacapavir for prevention.

Separately, during a press briefing on Monday, the U.S. Department of State’s Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, Ambassador John Nkengasong, discussed PEPFAR’s Aids response plan for Africa. Nkengasong asked governments to take ownership and lead the way in the HIV/AIDS response.